Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies
dc.contributor.author | Sintov, Amnon | en_US |
dc.contributor.author | Scott, William A. | en_US |
dc.contributor.author | Dick, Macdonald II | en_US |
dc.contributor.author | Levy, Robert J. | en_US |
dc.date.accessioned | 2006-04-07T20:06:41Z | |
dc.date.available | 2006-04-07T20:06:41Z | |
dc.date.issued | 1988-12 | en_US |
dc.identifier.citation | Sintov, Amnon, Scott, William, Dick, Macdonald, Levy, Robert J. (1988/12)."Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies." Journal of Controlled Release 8(2): 157-165. <http://hdl.handle.net/2027.42/27025> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T3D-475TC76-MX/2/0b85fc3c40bc786aa57dddbdb7f6a006 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/27025 | |
dc.description.abstract | Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium is reported. Lidocaine-HCl-polyurethane matrices (28% w/w) were fabricated and studied for their in vitro drug release into physiologic buffer, and their in vivo pharmacologie effectiveness in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. In vitro lidocaine release was successfully modulated as a result of variations in fabrication: compression molding, and stirring during polymer synthesis. Lidocaine release in vitro from the most rapidly releasing matrix formulation delivered more than 40% of the contained drug delivered after only 20 minutes, and the remainder slowly released over one week or more. Direct epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm in all experimental animals (n = 6) studied in 1.5 +/- 0.77 min(mean +/- standard error), while controls (n = 4) had persistent ventricular tachycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine-polyurethane controlled release matrices can be fabricated with a broad range of initial release profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm. | en_US |
dc.format.extent | 1035622 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The Division of Pediatrie Cardiology, C.S. Mott Children's Hospital; The Department of Pediatrics, The University of Michigan Medical School; The Department of Pharmaceutics, The College of Pharmacy of the University of Michigan, Ann Arbor, MI 48 109, U.S.A. | en_US |
dc.contributor.affiliationum | The Division of Pediatrie Cardiology, C.S. Mott Children's Hospital; The Department of Pediatrics, The University of Michigan Medical School; The Department of Pharmaceutics, The College of Pharmacy of the University of Michigan, Ann Arbor, MI 48 109, U.S.A. | en_US |
dc.contributor.affiliationum | The Division of Pediatrie Cardiology, C.S. Mott Children's Hospital; The Department of Pediatrics, The University of Michigan Medical School; The Department of Pharmaceutics, The College of Pharmacy of the University of Michigan, Ann Arbor, MI 48 109, U.S.A. | en_US |
dc.contributor.affiliationum | The Division of Pediatrie Cardiology, C.S. Mott Children's Hospital; The Department of Pediatrics, The University of Michigan Medical School; The Department of Pharmaceutics, The College of Pharmacy of the University of Michigan, Ann Arbor, MI 48 109, U.S.A. | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/27025/1/0000013.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0168-3659(88)90042-9 | en_US |
dc.identifier.source | Journal of Controlled Release | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.